FAP and neuroendocrine neoplasm: With 68Ga-DOTA-TATE and 177Lu-DOTA-TATE approved by the FDA, the development of somatostatin (SS) peptide analogistic for the detection and treatment of neuroendocrine tumors has been fruitful, and fibroblast-activating protein-alpha (FAP) targeting radiolands has recently shown high diagnostic potential.